E-drug: Ingelfinger rule (cont)
---------------------------------------------
The article is seen at; http://www.nejm.org/content/yusuf/1.asp
which is named "Effects of an Angiotensin-Converting-Enzyme Inhibitor,
Ramipril, on Death from Cardiovascular Causes, Myocardial Infarction, and
Stroke in High-Risk Patients".
And at the top of the page a notification is written;
"Notice: Because of its potential therapeutic implications, this article is
being released before its publication date, in accordance with the
Journal's policy (Angell M and Kassirer JP. The Ingelfinger Rule revisited.
N Engl J Med 1991;325:1371-2). The final version of the report will be
published on January 20, 2000. (Notice posted
November 10, 1999.)"
Was the Ingelfinger Rule broken by NEJM ?
Saio,Takeo MD.
Ando Hospital,Japan
72-1,Hanike Karausu-cho,Tsushima,496-0026,Japan
Tel;+81-567-31-4070 FAX;+81-567-32-1482
e-mail; saio@ppp.bekkoame.ne.jp
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.